Studies from Japan, the USA, and South Korea have all indicated that elevated β2-microglobulin levels are predictive of poor progression-free survival (PFS) and overall survival (OS) in DLBCL patients receiving various treatments [6, 32–34]. This evidence concerns the gene HLA-G and diffuse large B-cell lymphoma.